Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Add To Watchlist

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > selective pressure

View:

Post by Gbathat on Jul 05, 2021 7:36am

selective pressure

One of the things that scares me regarding the current COVID situation is the concept of evolutionary selective pressure. Basically, when you have a large (vaccinated) population that is resistant to a disease mingling with a large population that is not resistant (unvaccinated), you have both a reservoir of the virus in which to propogate facing an increasing degree of selective pressure for mutants/variants that may evade the immunity mechanism.

I thought this was a nice explanation of the issue.
https://www.mpg.de/16371358/coronavirus-variants

For this reason, I think it is critical to have tools like that being developed by PMN/BCNI via Immusafe and covidimmunitypassports.com

I was really impressed that the immusafe prototype was updated so quickly to address the delta and other variants. It seems to be an agile approach.

174